Traditional Chinese medicine is showing a vigorous trend of old trees and new shoots, and the multi-faceted layout of pharmaceutical companies ushered in new growth

 The development of traditional Chinese medicine has become a key point for a "healthy China.
" In recent years, with the continuous favorable policies of traditional Chinese medicine, the development of traditional Chinese medicine has shown a vigorous trend of old trees and new shoots
.
Nowadays, traditional Chinese medicine health has become the focus of attention of the whole society.
In this context, many companies have deployed traditional Chinese medicine health in various ways and ushered in new growth
.
Take Hongri Pharmaceutical as an example.
As early as its establishment, it was proposed to combine tradition with the future, and on the basis of maintaining integrity and innovation, allowing the continuous integration of Chinese medicine and Internet technology, the courage to innovate, and the persistence of open development
.
With continuous R&D and technological progress, Hongri Pharmaceutical has created a brand-new Chinese medicine formula granule technology-Kangrentang "All Ingredients®" Chinese medicine formula granules
.
While inheriting the traditional Chinese medicine decoctions, the dosage form reform is carried out, the traditional experience is digitally characterized, and the modern industrialized equipment is used for processing, which not only maintains the taste and efficacy of traditional Chinese medicine decoction pieces, but also greatly facilitates the consumption of patients.
The competitiveness of Hongri Pharmaceuticals may have been further improved in the construction of the big health field of Chinese medicine
.
Take Buchang Pharmaceutical as an example.
It has been committed to promoting the innovation and development of traditional Chinese medicine.
At present, it has formed a Chinese patent medicine as the core, based on the cardio-cerebrovascular market, covering the traditional advantages of Chinese patent medicine, focusing on major diseases, and cultivating large varieties.
Three-dimensional product layout
.
According to public information, in the first half of 2021, Buchang Pharmaceutical’s four varieties of Naoxintong Capsules, Wenxin Granules, Danhong Injection and Guhong Injection totaled 3.
279 billion yuan in sales revenue.
The revenue accounted for approximately 44.
39%; in addition to the two varieties in the chemical and biological medicine fields-compound brain peptide ganglioside injection and compound treotide injection, six products will be launched in Buchang Pharmaceutical in the first half of 2021.
The total income reached 4.
427 billion yuan, accounting for nearly 60% of the income
.
At present, the industrialization of Chinese medicine in my country is ushering in a period of important development opportunities
.
According to the data, the performance of the semi-annual report of the Chinese medicine sector this year is beautiful.
There are 73 listed companies in the Chinese medicine sector.
In the first half of 2021, the total operating income has increased by 15.
12% year-on-year to 162.
2 billion yuan; the total net profit attributable to shareholders of listed companies has increased year-on-year.
25.
05%, or 24.
2 billion yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses increased by 27.
56% year-on-year to 17 billion yuan
.
Among them, in the first half of 2021, among the companies with better net profits attributable to shareholders of listed companies, Baiyunshan 2.
502 billion yuan, Yunnan Baiyao 1.
802 billion yuan, China Resources 391.
365 billion yuan, Pien Tze Huang 1.
115 billion yuan, and Tasly 1.
02 billion yuan
.
Some institutions predict that, with the help of a series of favorable national policies, it is expected that in the second half of this year, listed companies in the Chinese medicine sector will still hand over a beautiful "transcript"
.
According to the industry, the performance growth of Chinese medicine companies is mainly due to the support of national policies and the expansion of the company's own market scale
.
"Guarantee from the legislative level, attaches importance to the strategic level, and promotes the development of Chinese medicine from every primary hospital.
From determination to specific measures, China's efforts to promote the development of Chinese medicine can be described as great
.
" Another person also said
.
It is understood that as a great creation of the Chinese nation and a treasure of ancient Chinese science, traditional Chinese medicine has always been the key direction of the country's continuous support and development
.
In recent years, the country has continued to promote the development of the Chinese medicine industry with favorable policies
.
For example, in 2021, China not only issued the "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" and proposed to encourage social capital to initiate the establishment of Chinese medicine industry investment funds, and increase long-term investment in the Chinese medicine industry
.
In addition, the National Human Rights Action Plan (2021-2025) was released, proposing to include the promotion of Chinese medicine in the right to health, and insisting on equal emphasis on Chinese and Western medicine and complementing each other's strengths, and vigorously develop the cause of Chinese medicine
.